Tag: weight reduction

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of...

Automotive Plastics Market to Reach $76.6 Billion by 2032, Growing at a CAGR of 7.8% from 2025, Says Meticulous Research®

Market Growth Driven by Lightweight Material Adoption, Cost-Effective Solutions, Advanced Manufacturing Technologies, and Expanding Electric Vehicle Applications REDDING, Calif., June 29, 2025 /PRNewswire/ -- According...

Automotive Plastics Market to Reach $76.6 Billion by 2032, Growing at a CAGR of 7.8% from 2025, Says Meticulous Research®

Market Growth Driven by Lightweight Material Adoption, Cost-Effective Solutions, Advanced Manufacturing Technologies, and Expanding Electric Vehicle Applications REDDING, Calif., June 29, 2025 /PRNewswire/ -- According...

Molicel and Darfon Energy Partner to Power the Next Generation of E-Bikes with the World’s Highest Energy Density Cell: INR-21700-M65A

TAIPEI, June 26, 2025 /PRNewswire/ -- Molicel, a pioneer in high-performance battery technology, and Darfon Energy, a leader in e-mobility power solutions, have announced...

AI-Driven Battery Management Systems Market to Reach $18.5 Billion by 2032, Growing at a CAGR of 20.6% from 2025, Says Meticulous Research®

Market Growth Powered by Electric Vehicle Expansion, Energy Storage Demand, Advanced Thermal Management Requirements, and Digital Twin Technology Integration REDDING, Calif., June 25, 2025 /PRNewswire/...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

Alvopetro Announces June 2025 Sales Volumes

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

Magna5 Ranks #39 on Channel Partners 2025 MSP 501 List

Tag: weight reduction

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

Automotive Plastics Market to Reach $76.6 Billion by 2032, Growing at a CAGR of 7.8% from 2025, Says Meticulous Research®

Automotive Plastics Market to Reach $76.6 Billion by 2032, Growing at a CAGR of 7.8% from 2025, Says Meticulous Research®

Molicel and Darfon Energy Partner to Power the Next Generation of E-Bikes with the World’s Highest Energy Density Cell: INR-21700-M65A

AI-Driven Battery Management Systems Market to Reach $18.5 Billion by 2032, Growing at a CAGR of 20.6% from 2025, Says Meticulous Research®

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us